ArticleCancer management and research2020
The Diagnostic and Prognostic Value of Serum lncRNA NEAT1 in Colorectal Cancer.
Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Expression Profiles and Biomarker Potential of Long Non-Coding RNAs H19, NEAT1, MALAT1 and HOTAIR in Locally Advanced Rectal Cancer Patients.International journal of molecular sciences · 2026Article
- The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer.Cancers · 2025Review
- The diagnostic value of LncRNA NEAT1 targeting miR-129-5p in pancreatic cancer patients.Scientific reports · 2025Article
- Discovery of lncRNA-Based ProsRISK Score in Serum as Potential Biomarkers for Improved Accuracy of Prostate Cancer Detection.Journal of cellular and molecular medicine · 2025Article
- The role of lncRNA NEAT1 in human cancer chemoresistance.Cancer cell international · 2024Review
- Meta-analysis of the correlation between high expression of lncRNA NEAT1 in rectal cancer and pathological features and prognosis.Journal of medical biochemistry · 2024Article
- Potentials of long non-coding RNAs as biomarkers of colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- KMT2B promotes the growth of renal cell carcinoma via upregulation of SNHG12 expression and promotion of CEP55 transcription.Cancer cell international · 2022Article
- Review
- Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690.Bioengineered · 2021Article
- Effects of Aerobic Exercise Training on MyomiRs Expression in Cachectic and Non-Cachectic Cancer Mice.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) is one of the most frequent types of gastrointestinal tract cancers. Abnormal expression of long non-coding RNAs (lncRNAs) has been shown to be closely associated with the progression of CRC. The aim of the current study was to determine the diagnostic and prognostic value of lncRNA nuclear paraspeckle assembly transcript 1 (NEAT1) in CRC.
methodsThe expression levels and diagnostic value of serum NEAT1 were evaluated in the training and validation cohorts. Then, the prognosis value of serum NEAT1 in CRC was further explored.
resultsThe expression levels of serum NEAT1 were significantly higher in CRC, especially in metastatic CRC, than in colorectal adenoma and healthy controls. In addition, serum NEAT1 could well differentiate metastatic CRC from non-metastatic CRC and CRC from colorectal adenoma or healthy controls. Moreover, the metastatic CRC cells secreted more NEAT1 than the control cells. Upregulation of serum NEAT1 was significantly associated with poor clinical outcome of CRC, and serum NEAT1 was identified as an independent prognostic factor for CRC.
conclusionSerum NEAT1 might be a promising diagnostic and prognostic biomarker for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.